U.S. Markets
Merck & Co. (MRK) says Phase 3 TroFuse-015 trial of sac-TMT improved overall survival in advanced gastroesophageal adenocarcinoma but did not meet its progression-free survival endpoint
ORIGINAL · NewsquawkMerck & Co. (MRK) says Phase 3 TroFuse-015 trial of sac-TMT improved overall survival in advanced gastroesophageal adenocarcinoma but did not meet its progression-free survival endpoint
StockNow breaking-news AI analysis
Merck said sac-TMT improved overall survival but missed the progression-free survival endpoint in TroFuse-015; an earlier Phase III result involved endometrial cancer.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
